Navigation Links
NIH grant to support Translational Research Center for PCOS
Date:5/12/2008

RICHMOND, Va. (May 12, 2008) The Virginia Commonwealth University School of Medicine has received a competitive grant totaling nearly $6 million from the National Institutes of Healths National Institute on Child Health & Human Development to examine polycystic ovary syndrome, a disorder of the endocrine system that affects as many as 5 million women.

Polycystic ovary syndrome, or PCOS, causes hormonal imbalances leading to irregular menstrual cycles, excess facial and body hair, weight gain and adult acne. Women with PCOS are at high risk for developing Type II diabetes and at increased risk for cardiovascular disease.

The five-year grant will support an interdisciplinary and translational research center in PCOS, making VCU one of only15 Specialized Cooperative Centers Program in Reproduction and Infertility Research (SCCPRIR) in the country.

This research program initiative expands the existing PCOS program at VCU, allowing interdisciplinary and collaborative studies with partnering institutions, and will enhance our ability to bring research discoveries from the laboratory bench quickly to the clinical care of women with PCOS, said John Nestler, M.D., vice chair of the Department of Internal Medicine and chair of the Division of Endocrinology and Metabolism at the VCU School of Medicine. Nestler, a pioneer in PCOS research, is the primary investigator for the project.

VCUs SCCPRIR program focuses on the use of genetics to identify risk for PCOS in an individual woman and pharmacogenomics, designed to identify the optimal treatment for an individual patient, he said.

The SCCPRIR is administered by the Reproductive Sciences Branch of the NICHD, and provides funding for a limited number of research centers in the reproductive sciences. The purpose of these centers is to provide an arena for multidisciplinary interactions among basic and clinical scientists interested in establishing high-quality programs in repr
'/>"/>

Contact: Sathy Achia Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Brainfood Awarded $25,000 Grant from General Mills Foundation through DC Mayor Fentys New Health Communities Program
2. St. Davids HealthCare Granted the States Top Honor for Quality and Performance Excellence
3. NIH awards LIAI major grant to test safety of new smallpox treatment
4. International Diabetes Federation gives grant to Philippine diabetes education program
5. Hospitals in Louisiana and Mississippi to Receive More Katrina Recovery Grants
6. NBCHs Community Coalitions Health Institute Receives CDC Grant
7. Making the Outdoors Safer for Communities: the American Academy of Dermatology Announces 2008 AAD Shade Structure Program Grant Recipients
8. USDA Grants Organic Certification to Ayalas Herbal Water(TM)
9. Courage Center Receives $150,000 Grant From Minneapolis Foundation
10. SCAI awards 46 grants for interventional cardiology training fellowships
11. Inscent, Inc. Receives Federal Grant to Develop Honeybee Repellents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...e/ -- Sciton introduces ProLipo,PLUS(TM), an FDA-...ser system,for ablating and melting unwanted fat,...tening. ProLipo PLUS combines 1064 nm and 1319 nm...ing results. Frequently used as an adjunct,to tr...a standalone procedure,for patients who are not c...
(Date:12/1/2008)...EER OF SCIENTIFIC DISCOVERY IN MOLECULAR IMAGING ,...he Radiologic Society of North America (RSNA) hono...ng Researcher of The Year" Award, recognition affo...al significant contributions to the field of radio...er is Professor at Harvard Medical School , as we...
(Date:12/1/2008)...f a million dollars to qualified recipients , ...ilepsy Company (TM), will honor 31 recipients of t...eception in Seattle, WA on Sunday, December 7 duri...The scholarship is awarded to inspiring people who...eek personal growth through higher learning. , ...
(Date:12/1/2008)...Newswire/ -- Transcept Pharmaceuticals,Inc., a p...nounced today that,Glenn A. Oclassen, President &...ticipate at the RBC Capital Markets 2008 Healthcar... "Delivering Novel Drug Solutions: The Future of D... take place on Thursday, December,11, 2008 at 1:3...
Breaking Medicine News(10 mins):Health News:Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 3Health News:Unique Scholarship Helps People Affected by Epilepsy Fulfill Life Ambitions 2Health News:Unique Scholarship Helps People Affected by Epilepsy Fulfill Life Ambitions 3Health News:Unique Scholarship Helps People Affected by Epilepsy Fulfill Life Ambitions 4Health News:Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel 2
...out 10 percent of women in their mid-20s and about...Women with poor memory // skills are also often i...lements may reverse memory loss in these women. Re...en ages 18 and 35. The women were either anemic, i...
...ows calcium from milk, supplements, or other dairy...oting weight loss ,// so if your mother always tol...he may have been wrong. Participants in the stud...ight. Researchers say if the body consumes enough ...
...eatment plan for Leukemia , doctors rely on indica... to be, // including how the cancer cells look und...story. However, for some patients, those indicator...-risk or low-risk group. Doctors may be left guess...
... happens when a clot blocks blood flow to the brai...ction on their own. //Now, a new study shows patie...oke appear to regain more functional independence ...y, researchers evaluated the outcomes of 167 strok...
Other Medicine News:
(Date:11/26/2008)...n., Nov. 26 Children wh...ignificantly increased risk of developing mental i...f a Mayo Clinic study published this month in Ped...demy of Pediatrics. , , The retrospective s...with strabismus (misaligned eyes) and compared the...
(Date:11/25/2008)... most respondents against expanding statin use bro...TLE FALLS, N.J., Nov. 25 JUPITER, ... the cardiovascular risk of healthy patients with ...se in older adults, according to a national poll d...ipants took part in the online poll conducted by m...
(Date:11/25/2008).... 25 CardioVascular,Bio...ounced today that it has,dosed the first patient ...I,clinical trial to treat patients with severe co... the treatment of CORonary heart Disease) trial wi...-controlled doses in approximately 120,patients w...
(Date:11/24/2008)...rms its innovation leadership and long-term commit...N.J., Nov. 24 Schering-P...clinical update on boceprevir, its lead investigat...y in Phase III development. The company believes ...s and best-in-class protease inhibitor for treatin...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9UCSF faculty receive 2413 7M from CIRM for stem cell research 25576 1UCSF faculty receive 2413 7M from CIRM for stem cell research 25576 2UCSF faculty receive 2413 7M from CIRM for stem cell research 25576 3Nurse Practitioner Healthcare Foundation Awards Scholarships to Leaders in Nursing 25574 1Nurse Practitioner Healthcare Foundation Awards Scholarships to Leaders in Nursing 25574 2Nurse Practitioner Healthcare Foundation Awards Scholarships to Leaders in Nursing 25574 3Nurse Practitioner Healthcare Foundation Awards Scholarships to Leaders in Nursing 25574 4VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 1VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 2VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 3VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 4VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 5VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 6VirtualHealth Technologies Inc Announces Its Associate Private Access Appoints Marc Kirshbaum as President 26 COO 25569 7New research on sexual function 25566 1New research on sexual function 25566 2
...ndicate early non-responders unlikely to subsequen...ts, and may benefit,from earlier change in treatme...07 /PRNewswire-FirstCall/,-- New data presented at...Research (ICOSR) suggest that antipsychotic drug,r...ght, and,challenge the current schizophrenia treat...
... Reduced By an Average of More Than Two Hours Per .../PRNewswire/ --,Adding the once daily, investigati...our(TM) Extended-Release Tablets to,Parkinson,s pa...cantly reduced ,off, time, allowing patients to co...of time. ,Off time,describes the return of Parkin...
Other Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5
...d for stone manipulation and removal in the urinar... to retain its shape following extreme torsion. Th...ture by allowing the basket to open at the base of...ign reduces the likelihood of mucosal damage and p...
Used to establish and maintain nephrostomy drainage following pyeloplasty. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; stent must not r
Used for percutaneous placement of a pigtail catheter in the renal pelvis for nephrostomy drainage. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is
The BioPlex 2200 system is a fully automated bead-based multiplexing immunoassay platform that can deliver up to 2200 results per hour. The system will initially include a panel of assays targeting a
Medicine Products: